Although the Smo inhibitor vismodegib is successful in treating BCN [99], only 48% of patients with advanced BCC respond to the drug [100], and further 20% of the BCC patients develop resistance within the first year of treatment [101]. The gene discussed is SMO; the disease is skin basal cell carcinoma.